Growth hormone/insulin-like growth factor axis in human immunodeficiency virus-associated disease

Endocrinologist

Volumn 7, Issue 1, 1997, Pages 23-31

  Frost, Robert A ^a   Lang, Charles H ^a   Gelato, Marie C ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN;

AIDS RELATED COMPLEX; FAILURE TO THRIVE; GROWTH HORMONE RELEASE; GROWTH REGULATION; GROWTH RETARDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEAN BODY WEIGHT; POSTNATAL GROWTH; PROTEIN PROCESSING; REVIEW; WEIGHT REDUCTION;

EID: 0031056879     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-199707010-00004     Document Type: Review

References (84)

1. Coodley GO, Loveless MO, Merrill TM: The HIV wasting syndrome: a review. J AIDS 1994; 7: 46-51.
2. Stein JP, Nutrinsky C, Condoluci D, et al.: Protein and energy substrate metabolism in AIDS patients. Metabolism 1990; 39: 876-81.
3. Macallan DC, Noble C, Baldwin C, et al.: Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995; 333: 83-8.
4. Kotler DP, Tierney AR, Culpepper-Morgan JA, et al.: Effect of home total patenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. J Parenter Enterai Nutr 1990; 14: 454-8.
5. Oster MH, Enders SR, Samuels SJ, et al.: Megesterol acetate in patients with AIDS and cachexia. Ann Int Med 1994; 121: 400-8.
6. Keusch GT, Farthing MJG: Nutritional aspects of AIDS. Ann Rev Nutr 1990; 10: 475-501.
7. Press M: Growth hormone and metabolism. Diabetes Metab Rev 1988; 4: 391-414.
8. Salomaon F, Cuneo R, Sonksen PH: Growth hormone and protein metabolism. Horm Res 1991; 36: 41-3.
9. Turkalj I, Keller U, Ninnis R, et al.: Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid and leucine metabolism in man. J Clin Endocrinol Metab 1992; 75: 1186-91.
10. Fryburg DA, Gelfand RA, Barrett EJ: Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am J Physiol 1991; 260: E499-504.
11. Fryburg DA: Insulin-like growth factor-I exerts growth hormone and insulin-like actions on muscle protein metabolism. Am J Physiol 1994; 267: E331-6.
12. Jurasinski CV, Vary TC: Insulin-like growth factor-I accelerates protein synthesis in skeletal muscle during sepsis. Am J Physiol 1995; 269: E977-81.
13. Ballard FJ, Read LC, Francis GF, et al.: Binding properties and biological potencies of insulin-like growth factors in L6 myoblasts. Biochem J 1986; 233: 223-30.
14. Roeder RA, Hossner KL, Sasser RG, et al.: Regulation of protein turnover by recombinant human insulin-like growth factor-I in L6 myotube cultures. Horm Metab Res 1988; 20: 698-700.
15. Ross RJM, Miell JP, Freeman E, et al.: Critically ill patients have high basal growth hormone concentrations with attenuated oscillatory activity associated with low concentrations of insulin-like growth factor I. Clin Endocrinol 1991; 35: 47-54.
16. Thissen J-P, Ketelslegers J-M, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80-101.
17. Gelato MC: Aging and immune function: a possible role for growth hormone. Horm Res 1996; 45: 46-9.
18. Wernerman J: Effect of growth hormone on muscle and protein in critically ill patients. Acta Endocrinologica (Copenh) 1993; 128(Suppl.2): 19-22.
19. Gore DC, Honeycutt D, Jahoor F, et al.: Effect of exogenous growth hormone on whole body and isolated limb protein kinetics in burn patients. Arch Surg 1991; 126: 38-43.
20. Pisters PW, Pearlstone DB: Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci 1993; 30: 223-72.
21. Tayek JA, Brasel J: Failure of anabolism in malnourished cancer patients receiving growth hormone. J Clin Endocrinol Metab 1995; 80: 2082-7.
22. Krentz AJ, Koster FT, Crist DM, et al.: Anthropometric, metabolic and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immun Defic Syndr 1993; 6: 245-51.
23. Rudman D, Kutner MH, Rogers CM: Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 1981; 67: 1361-6.
24. Gelato MC, Frost RA, DeCristofaro K, et al.: Growth hormone deficiency and diminished anabolic response in muscle of HIV infected adults. The Endocrine Society Annual Meeting 1996; Abstract P3-44.
25. Grinspoon S, Corcoran C, Lee K, et al.: Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996; 81: 4051-8.
26. Heijligenberg R, Brabant G, Endert E, et al.: Circadian growth hormone secretion in asymptomatic human immune deficiency virus syndrome infection and acquired immuno deficiency syndrome. J Clin Endocrinol Metab 1996; 81: 4028-32.
27. Wilson LD, Truong MPM, Barber AR, et al.: Anterior pituitary and pituitary target organ function in men infected with the human immunodeficiency virus. Metabolism 1996; 45: 738-46.
28. Howard AD, Feighner SD, Cull DF, et al.: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-7.
29. Tshikuka JG, Torres-Anjel MJ, Blenden DC, et al.: The microepidemiology of wasting syndrome, a common link to diarrheal disease, cancer rabies, animal models of AIDS. Ann NY Acad Sci 1992; 653: 274-96.
30. Buzy J, Brenneman DE, Pert CB, et al.: Potent gp120-like neurotoxic activity in the cerebrospinal fluid of HIV-infected individuals is blocked by peptide T. Brain Res 1992; 598: 10-8.
31. Ferreiro J, Vinters HV: Pathology of the pituitary gland in patients with the acquired immune deficiency syndrome (AIDS). Pathology 1988; 20: 211-5.
32. Lumpkin MD, McDonnell KJ, Mulroney SE, et al.: Human immunodeficiency virus (HIV) envelope protein gp120 acts rapidly in the brain to inhibit growth hormone secretion. The Endocrine Society Annual Meeting 1995; Abstract P3-95.
33. Lumpkin MD, Samson WK, Mulroney SE, et al.: Human immunodeficiency virus (HIV) envelope protein gp120 acts directly on pituitary cells to inhibit growth hormone secretion. The Endocrine Society Annual Meeting 1996; Abstract P2-330.
34. Mulligan K, Grunfeld C, Hellerstein MK, et al.: Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77: 956-62.
35. Frost RA, Fuhrer J, Steigbigel R, et al.: Wasting in the acquired immune deficiency syndrome is associated with multiple defects in th serum insulin-like growth factor system. Clin Endocrinol 1996; 44: 501-14.
36. Lee PDK, Pivarnik JM, Bukar JG, et al.: A randomized, placebocontrolled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996; 81: 2968-75.
37. Geffner ME, Yeh DY, Landaw EM, et al.: In vitro insulin-like growth factor-I, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1 infected children. Ped Res 1993; 34: 66-72.
38. Levitt LE, Rosenfeld RG, Cohen PC: Clinical significance of insulin-like growth factor binding proteins. Endocrinologist 1995; 5: 36-43.
39. Daughaday WH, Ward AP, Goldberg AC, et al.: Characterization of somatomedin binding in human serum by ultracentrifugation and gel filtration. J Clin Endocrinol Metab 1982; 55: 916-21.
40. Hodgkinson SC, Davis SR, Moore LG, et al.: Metabolic clearance of insulin-like growth factor-11 in sheep. J Endocrinol 1989; 123: 461-8.
41. Baxter RC: Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994; 42: 140-4.
42. Jones JI, Gockerman A, Busby WH, et al.: Insulin-like growth factor binding protein-1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 1993; 90: 10553-7.
43. Frost RA, Tseng L: Insulin-like growth factor binding protein-1 is phosphorylated by cultured human endometrial stromal cells and multiple protein kinases in titro. J Biol Chem 1991; 266: 18082-8.
44. Jones JI, D'Ercole AS, Camacho-Hubner C, et al.: Phosphorylation of insulin-like growth factor binding protein-1 in cell culture and in livo: effects on affinity for IGF-I. Proc Natl Acad Sci 1991; 88: 7481-5.
45. Irving JA, Lala PK: Functional role of cell surface integrins on human trophoblast cell migration: regulation by TGF-beta, IGF-II and IGFBP-I. Exp Cell Res 1995; 217: 419-27.
46. Lassarre C, Binoux M: Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology 1994; 134: 1254-62.
47. Lalou C, Lassarre C, Binoux M: A proteolytic fragment of insulin-like growth factor binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996; 137: 3206-12.
48. Frost VJ, Helle SI, Lonning PE, et al.: Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 1996; 81: 2216-21.
49. Wojnar MM, Fan J, Frost RA, et al.: Alterations in the insulin-like growth factor system in trauma patients. Am J Physiol 1995; 268: R970-7.
50. Lang CH, Fan J, Frost RA, et al.: Regulation of the insulin-like growth factor system by insulin in burn patients. J Clin Endocrinol Metab 1996; 81: 2474-30.
51. Bereket A, Lang CH, Blethen SL, et al.: Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282-6.
52. Hall K, Enberg G, Hellem E: Somatomedin levels in pregnancy: longitudinal study in healthy subjects and patients with growth hormone deficiency. J Clin Endocrinol Metab 1984; 59: 587-94-
53. Yee D, Vandenberg CL, Kozelsky TW, et al.: Pharmacokinetic profile of recombinant human insulin-like growth factor binding protein-1 in athymic mice. Biomed Pharm 1996; 50: 154-7.
54. Holly JMP: The physiological role of IGFBP-I. Acta Endocrinologica (Copenh) 1991; 124: 55-62.
55. Lee PDK, Conover CA, Powell DR: Regulation and function of insulin-like growth factor binding protein-1. Proc Soc Exp Biol Med 1993; 204: 4-29.
56. Suwanickul A, Morris SL, Powell DR: Identification of an insulin responsive element in the promoter of the human gene for insulin-like growth factor binding protein-1. J Biol Chem 1993; 268: 17063-8.
57. Bar RS, Clemmons DR, Boes M: Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid insulin-like growth factor binding proteins in the rat heart. Endocrinology 1990; 127: 1078-86.
58. Fan J, Molina PE, Gelato MC, et al.: Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 1994; 134: 1685-92.
59. Fan J, Char D, Bagby GJ, Gelato MC, et al.: Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am J Physiol 1995; 38: R1204-12.
60. Fan J, Wojnar M, Theodorakis M, et al.: Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1. Am J Physiol 1996; 39: R621-9.
61. Grunfeld C, Feingold KR: The role of the cytokines, Interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr 1992; 122: 749-53.
62. Tracey KJ, Morgello S, Koplin B: Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. J Clin Invest 1990; 86: 2014-24.
63. Frost RA, Berekett A, Wojnar MM, et al.: Phosphorylation of human insulin-like growth factor binding protein-1 in patients with insulin-dependent diabetes mellitus and severe trauma. J Clin Endocrinol Metab 1994; 78: 1533-5.
64. Ho KY, Veldhuis JD, Johnson ML et al.: Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 1988; 81: 968-75.
65. Rasmussen MH, Hvidberg A, Julul A, et al.: Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995; 80: 1407-15.
66. Underwood LE, Thissen JP, Lemozy S, et al.: Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994; 42: 145-51.
67. Blum WF, Ranke MB: Use of insulin-like growth factor-binding protein-3 for the evaluation of growth disorders. Horm Res 1990; 33: 31-7.
68. Laurence J: Growth hormone in HIV/AIDS: current uses and future prospects. Fed AIDS HIV Infect 1995; 6: 281-91.
69. LeRoith D, Unesco J, Kaldjian EP, et al.: The effects of growth hormone and insulin-like growth factor I on the immune system of aged female monkeys. Endocrinology 1996; 137: 1071-9.
70. Hokken-Koelega AC, Stijnen T, de Ridder MA et al.: Growth hormone treatment in growth-retarded adolescents after renal transplant. Lancet 1994; 343: 1313-7.
71. Laurence J, Grimison B, Gonenne A: Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro. Blood 1992; 79: 467-72.
72. Germinario RJ, DeSantis T, Wainberg MA: Insulin-like growth factor 1 and insulin inhibit HIV type 1 replication in cultured cells. AIDS Res Human Retrov 1995; 11: 555-61.
73. Lieberman SA, Butterfield GE, Harrison D, et al.: Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994; 78: 404-10.
74. Ellis KJ, Lee PDK, Pivarnik JM, et al.: Changes in body composition of HIV infected males receiving growth hormone and insulin-like growth factor-I. J Clin Endocrinol Metab 1996; 81: 3033-8.
75. Jorgensen JOL: Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr Rev 1991; 12: 189-207.
76. Lepage P, Van de Pere P, Van Vliet G: Clinical and endocrinologie manifestations in perinatally human immunodeficiency virus type-1 infected children aged 5 years or older. Am J Dis Child 1991; 145: 1248-51.
77. Laue L, Pizzo PA, Butler K, et al.: Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. J Pediatr 1990; 117: 541-5.
78. Schwartz LJ, St Louis Y, Wu R, et al.: Endocrine function in children with human immunodeficiency virus infection. Am J Dis Child 1991; 145: 330-3.
79. Matarazzo P, Palomba E, Lala R, et al.: Growth impairment, IGF-I hyposecretion and thyroid dysfunction in children with perinatal HIV-I infection. Acta Paediatr 1994; 83: 1029-34.
80. Frost RA, Nachman SA, Lang CH, et al.: Proteolysis of insulin-like growth factor binding protein-3 in human immunodeficiency vieus positive children who fail to thrive. J Clin Endocrinol Metab 1996; 81: 2957-62.
81. Tarantal AF, Marthas ML, Gargosky SE, et al.: Effects of viral virulence on intrauterine growth in SIV-infected fetal rhesus macaques. J Acquir Immun Def Synd Hum Retrov 1995; 10: 129-38.
82. Klotman PE, Rapp'aport J, Ray P, et al.: Transgenic models of HIV-1. AIDS 1995; 9: 313-24.
83. Chin E, Zhou J, Dai J, et al.: Cellular localization of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology 1994; 134: 2498-504.
84. Hirshfeld S, Tudor-Williams G, Stocker V, et al.: Effects of recombinant human growth hormone and recombinant insulin-like growth factor-I administration in children with human immunodeficiency virus infection and growth failure. Natl Conf Hum Retrov Relat Infect 1995; Abstract 149.